These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27245553)

  • 21. mPEG
    Zhang Y; Sun M; Jian S; Huang J; Xiao C; Zhang X; Hu R; Si L
    Mol Pharm; 2021 Jul; 18(7):2586-2599. PubMed ID: 34102842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
    Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
    Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
    Müller F; Weitz D; Mertsch K; König J; Fromm MF
    Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.
    Flory J; Haynes K; Leonard CE; Hennessy S
    Br J Clin Pharmacol; 2015 Feb; 79(2):330-6. PubMed ID: 25199921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
    Zhang G; Ma Y; Xi D; Rao Z; Sun X; Wu X
    Biopharm Drug Dispos; 2019 Jan; 40(1):3-11. PubMed ID: 30488476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects.
    Jang K; Chung H; Yoon JS; Moon SJ; Yoon SH; Yu KS; Kim K; Chung JY
    J Clin Pharmacol; 2016 Sep; 56(9):1104-10. PubMed ID: 26710683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
    Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
    Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
    Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
    Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
    Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
    Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
    Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.
    Li Q; Yang H; Guo D; Zhang T; Polli JE; Zhou H; Shu Y
    Drug Metab Dispos; 2016 Apr; 44(4):489-94. PubMed ID: 26825640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
    Sambol NC; Chiang J; O'Conner M; Liu CY; Lin ET; Goodman AM; Benet LZ; Karam JH
    J Clin Pharmacol; 1996 Nov; 36(11):1012-21. PubMed ID: 8973990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
    Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin.
    Kwon M; Choi YA; Choi MK; Song IS
    Arch Pharm Res; 2015; 38(5):849-56. PubMed ID: 25359200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
    Xiao G; Rowbottom C; Boiselle C; Gan LS
    Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats.
    Ma YR; Huang J; Shao YY; Ma K; Zhang GQ; Zhou Y; Zhi R; Qin HY; Wu XA
    Eur J Pharm Sci; 2015 Feb; 68():18-26. PubMed ID: 25486332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.